A Case with Diagnosed Multiple Sclerosis in Advanced Age

Öz

Multiple sclerosis (MS) causes functional loss in different areas of central nervous system and, various clinical findings. Progress of MS could distinguish in same patient in different times as well as among different patients. We presented a female patient with diagnosed MS in 60 years old. Her complaints began in good clinical progress in young adult life. She had been observed prominent progression in clinical course after 58 years old. The aim of this article to discuss the choices of diagnosis and treatment in patients advanced ages.

Anahtar Kelimeler

• -

İleri Yaşta Multipl Skleroz Tanısı Alan Bir Olgu

Öz

Multipl skleroz (MS), merkezi sinir sisteminin farklı alanlarına ait işlev kaybına ve çok çeşitli klinik tablolara yol açabilen bir hastalıktır. Klinik tablolardaki heterojenite hastalığın seyrinde de göze çarpmaktadır. MS'in seyri hastadan hastaya ve aynı hastanın kendi klinik seyri içinde de farklılıklar gösterebilmektedir. Bu yazıda klinik belirtileri genç erişkin yaşta başlayan, ileri yaşa kadar nispeten iyi bir klinik seyri olan fakat 58 yaşından sonra klinik olarak belirgin kötüleşme gözlenen ve MS tanısını ilk olarak 60 yaşında alan bir olgu, ileri yaştaki hastalarda tanı ve tedavi seçeneklerini gözden geçirmek amacıyla tartışılmıştır.

Anahtar Kelimeler

• Multipl skleroz, ikincil ilerleyici, tanı, prognoz

Kaynakça

1. 1. Eraksoy M, Akman Demir G. Merkezi Sinir Sisteminin myelin hastalıkları. Öge EA (Editör). Nöroloji:Đ.Ü. Đstanbul Tıp Fakültesi Temel ve Klinik Bilimler Ders Kitapları. 1.baskı, Đstanbul: Nobel Tıp Kitabevleri 2004: 505-534.
2. 2. Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 2006; 54 :149-153.
3. 3. Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127(Pt 6):1353-1360.
4. 4. Paavilainen T, Kurki T, Parkkola R et al. Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. Eur J Neurol 2007; 14: 1216- 1221.
5. 5. Saraste M, Väisänen S, Alanen A, Airas L. Clinical and immunologic evaluation of women with multiple sclerosis during and after pregnancy. Gend Med 2007; 4:45-55.
6. 6. Smith R, Studd JW. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J R Soc Med 1992; 85: 612-613.
7. 7. Tunalı G. Multipl sklerozda tanı kriterleri. Türkiye Klinikleri Nöroloji Dergisi 2004; 2: 205-209.
8. 8. Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004; 25 (Suppl 4): 350- 355.

9. 9. de Seze J, Delalande S, Michelin E, et al. Brain MRI in lateonset multiple sclerosis. Eur J Neurol 2005;12: 241-244.
10. 10. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003; 206:135-137.
11. 11. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252 (Suppl 3):15-20.
12. 12. Eraksoy M. .Multipl sklerozda immun modulatör tedaviler. Türkiye Klinikleri Nöroloji Dergisi 2004; 2: 228-231.
13. 13. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313):1221-1231.
14. 14. Río J, Tintoré M, Nos C et al. Interferon beta in secondary progressive multiple sclerosis: daily clinical practice. J Neurol 2007; 254: 849-853.
15. 15. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004;18: 379-396.
16. 16. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
17. 17. Millefiorini E, Gasperini C, Pozzilli C et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244:153-159.
18. 18. Hartung HP, Gonsette R, König N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet 2002; 360: 2018- 2025.
19. 19. Tunalı G. Multipl sklerozda immunsupresyon tedavisi. Türkiye Klinikleri Nöroloji Dergisi 2004; 2: 223-227.